| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA |
| Website |
http://www.wjgnet.com |
| Specialty |
Gastroenterology and Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, George Peros, Stefanos Konstantoudakis, Danai Leventakou, Ioannis G Panayiotides, Petros Karakitsos and Anna Koumarianou |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Kapodistrias, National and Kapodistrian University of Athens |
70/3/8006 |
| Kapodistrias, National and Kapodistrian University of Athens |
70/3/9114 |
| Spathis A was supported during data collection |
70/3/8462 |
|
| Correspondence To |
Anastasios Ntavatzikos, MD, Research Scientist, Surgeon, Hematology-Oncology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Rimini 1, Haidari 12462, Athens, Greece. dmaal2@yahoo.gr |
| Keywords |
Thymidylate synthase; Polymorphisms; mCRC; Loss of heterozygosity; Survival; Chemotherapy; KRAS; BRAF; TYMS |
| Core Tip |
The etiology of resistance to new targeted agents and chemotherapy is currently being investigated based upon the patients’ genetic profile in order to develop a prognostic model that could lead to individualized treatment. In this context, we studied the effect of thymidylate synthase (TYMS) polymorphisms that have been described so far, taking into account the presence of KRAS and BRAF mutations in association with the treatment. TYMS 3’ untranslated region polymorphism ins/ins and ins/loss of heterozygosity emerged as an independent factor that increases the risk of both disease progression and death. Regimens that included irinotecan had reduced risk of disease progression and death. |
| Publish Date |
2017-08-28 06:54 |
| Citation |
Ntavatzikos A, Spathis A, Patapis P, Machairas Ν, Peros G, Konstantoudakis S, Leventakou D, Panayiotides IG, Karakitsos P, Koumarianou A. Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. World J Gastroenterol 2017; 23(32): 5913-5924 |
| Url |
http://www.wjgnet.com/1007-9327/full/v23/i32/5913.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i32.5913 |
